Search results for "Small"

showing 10 items of 2441 documents

Poor mothers, unhealthy children: the transmission of health inequalities in the INMA study, Spain

2019

Background The health of pregnant women and their fetuses are especially sensitive to socioeconomic conditions. This study analyzes the impact of maternal socioeconomic status (SES), evaluated by occupation and maternal education level, in preterm births (PTBs) and in small for gestational age (SGA) fetuses, considering the effect of the potential mediating factors on the SES and birth outcomes. Methods A total of 2497 mother/newborn dyads from the INMA-Spain project were studied. We examined maternal occupation and education in relation to PTB and SGA along with covariate data, using logistic regression analysis. Adjusted models for each of the outcome variables in relation to SES indicato…

AdultMaleGerontologyInequalityBody mass index proceduremedia_common.quotation_subjectMothersSocioeconomic factorsWeight Gain03 medical and health sciencesFetus0302 clinical medicinePregnancyRisk FactorsPolitical scienceHumansUnderweight030212 general & internal medicineOccupationsChildmedia_commonHealth disparityEducational status030503 health policy & servicesSmokingInfant NewbornPregnancy OutcomePublic Health Environmental and Occupational HealthInfantBirth outcomeSmall for gestational ageHealth Status DisparitiesPregnancy ComplicationsSocial ClassSpainEducational StatusPremature BirthFemaleChristian ministryPregnant Women0305 other medical scienceHumanitiesMaternal AgeEuropean Journal of Public Health
researchProduct

A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease

2007

BACKGROUND: Treatment of celiac disease (CD) is based on the avoidance of gluten-containing food. However, it is not known whether trace amounts of gluten are harmful to treated patients. OBJECTIVE: The objective was to establish the safety threshold of prolonged exposure to trace amounts of gluten (ie, contaminating gluten). DESIGN: This was a multicenter, double-blind, placebo-controlled, randomized trial in 49 adults with biopsy-proven CD who were being treated with a gluten-free diet (GFD) for > or =2 y. The background daily gluten intake was maintained at < 5 mg. After a baseline evaluation (t0), patients were assigned to ingest daily for 90 d a capsule containing 0, 10, or 50 mg glute…

AdultMaleGluten free diet Celiac Diseasemedicine.medical_specialtyGlutensPlacebo-controlled studyMedicine (miscellaneous)gastroenterologyDiseasedigestive systemGastroenterologyCoeliac diseaselaw.inventionRandomized controlled trialDouble-Blind Methodgluten-free dietlawInternal medicineImmunopathologyIntestine SmallMedicineHumansgluten toxicitysmall-intestinal morphometryLymphocyte CountProspective StudiesIntestinal MucosaProspective cohort studyAutoantibodiesceliac disease; gastroenterology; gluten threshold in gluten-free food; gluten threshold in gluten-free food.; gluten toxicity; gluten-free diet; small-intestinal morphometrychemistry.chemical_classificationNutrition and DieteticsDose-Response Relationship Drugbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseGlutendigestive system diseasesgluten threshold in gluten-free foodchemistryToxicityFemalebusinessceliac disease
researchProduct

Socioeconomic inequalities in injury mortality in small areas of 15 European cities.

2013

This study analysed socioeconomic inequalities in mortality due to injuries in small areas of 15 European cities, by sex, at the beginning of this century. A cross-sectional ecological study with units of analysis being small areas within 15 European cities was conducted. Relative risks of injury mortality associated with the socioeconomic deprivation index were estimated using hierarchical Bayesian model. The number of small areas varies from 17 in Bratislava to 2666 in Turin. The median population per small area varies by city (e.g. Turin had 274 inhabitants per area while Budapest had 76,970). Socioeconomic inequalities in all injury mortality are observed in the majority of cities and a…

AdultMaleHealth (social science)AdolescentUrban PopulationGeography Planning and DevelopmentPopulationPoison controlSocial class03 medical and health sciencesYoung Adult0302 clinical medicineEnvironmental healthInjury preventionHumansSocioeconomic inequalities030212 general & internal medicineMortalityHealthcare DisparitieseducationSocioeconomicsUrban areasSocioeconomic statusSmall-Area Analysiseducation.field_of_study030505 public healthInjuries1. No povertyPublic Health Environmental and Occupational HealthEcological studyMiddle Aged3. Good healthEastern europeanEuropeGeographySmall areasCross-Sectional StudiesSocial ClassSmall-Area AnalysisWounds and InjuriesFemale0305 other medical scienceHealthplace
researchProduct

Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern…

2005

We tested the hypothesis that gemfibrozil has a differential effect on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclass distributions and postprandial lipemia that is different in subjects classified as having LDL subclass pattern A or LDL pattern B who do not have a classic lipid disorder. Forty-three normolipemic subjects were randomized to gemfibrozil (1,200 mg/day) or placebo for 12 weeks. Lipids and lipoproteins were determined by enzymatic methods. The mass concentrations of lipoproteins in plasma were determined by analytic ultracentrifugation and included the S(f) intervals: 20 to 400 (very LDL), 12 to 20 (intermediate-density lipoprotein), 0 to 12 (LDL), an…

AdultMaleHyperlipoproteinemiasmedicine.medical_specialtySmall dense ldlLipid disorderApolipoprotein BLipoproteins VLDLPlacebochemistry.chemical_compoundDouble-Blind MethodInternal medicinemedicineHumansGemfibrozilTriglyceridesAgedHypolipidemic Agentsbiologybusiness.industryMiddle AgedPostprandial PeriodLipoproteins LDLTreatment OutcomeEndocrinologyPostprandialchemistryLow-density lipoproteinbiology.proteinFemalelipids (amino acids peptides and proteins)GemfibrozilLipoproteins HDLCardiology and Cardiovascular MedicinebusinessGemfibrozil small low-density lipoprotein pattern B pattern ABiomarkersLipoproteinmedicine.drug
researchProduct

Objective measurement of intraocular forward light scatter using Hartmann-Shack spot patterns from clinical aberrometers. Model-eye and human-eye stu…

2007

Purpose To apply software-based image-analysis tools to objectively determine intraocular scatter determined from clinically derived Hartmann-Shack patterns. Setting Aston Academy of Life Sciences, Aston University, Birmingham, United Kingdom, and Department of Optics, University of Valencia, Valencia, Spain. Methods Purpose-designed image-analysis software was used to quantify scatter from centroid patterns obtained using a clinical Hartmann-Shack analyzer (WASCA, Zeiss/Meditec). Three scatter values, as the maximum standard deviation within a lenslet for all lenslets in the pattern, were obtained in 6 model eyes and 10 human eyes. In the model-eye sample, patterns were obtained in 4 sessi…

AdultMaleLightPsychometricsIntraclass correlationLensletDiagnostic Techniques OphthalmologicalEyeRefraction OcularModels BiologicalSensitivity and SpecificityStandard deviationOpticsmedicineImage Processing Computer-AssistedHumansScattering RadiationMathematicsbusiness.industryObjective measurementCentroidReproducibility of ResultsSmall sampleRepeatabilitySensory SystemsOphthalmologymedicine.anatomical_structureOptometrySurgeryHuman eyeFemalebusinessJournal of cataract and refractive surgery
researchProduct

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Pr…

2004

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with extensive disease (ED-SCLC). Methods: Chemonaive ED-SCLC patients received cisplatin 30 mg/sqm, epirubicin 50 mg/sqm and paclitaxel 120 mg/sqm, weekly, with G-CSF (5 μg/kg from day 3 to 5) support, for a maximum of 12 weeks. Results: Thirty-nine patients were treated, for a total of 354 cycles delivered. Eight complete (21%), and 22 partial responses (56%) were recorded, giving a 77% (95% Cl = 61-89%) objective response rate (ORR). After 14 (rang…

AdultMaleLung NeoplasmsPaclitaxelMiddle AgedPrognosisSmall-cell lung cancer Weekly chemotherapy Paclitaxel Epirubicin CisplatinSurvival AnalysisDrug Administration ScheduleTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansFemaleCarcinoma Small CellCisplatinInfusions IntravenousAgedEpirubicin
researchProduct

Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

2016

BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Twenty patients with stage IV NSCLCwere enrolled prospectively. PET/CT studies were performed before, then 48 hours, and 45 days after…

AdultMaleLung NeoplasmsTime FactorsAntineoplastic AgentsKaplan-Meier EstimateAdult; Aged; Antineoplastic Agents; Carcinoma Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Time Factors; Treatment OutcomeResponse evaluation criteria in solid tumorDisease-Free SurvivalErlotinib Hydrochloridenon–small cell lung cancerPositron Emission Tomography Computed TomographyHumansProspective StudiesNon-Small-Cell LungAgedCarcinomaMiddle AgedCarcinoma non-small-cell lungEORTCTreatment OutcomeRECISTResponse evaluation criteria in solid tumorsFemalePositron-emission tomographyPERCISTDiagnosi18F-FDG PET
researchProduct

Optical coherence tomography of macular thickness after biaxial vs coaxial microincision clear corneal cataract surgery

2009

PURPOSE To evaluate macular thickness changes after biaxial microincision versus coaxial small incision cataract surgery using optical coherence tomography (OCT). METHODS This prospective, randomized, marked study comprised 70 patients (70 eyes) undergoing biaxial microincision surgery or conventional coaxial phacoemulsification. Patients were evaluated by Stratus OCT preoperatively and 1 day, 4 weeks, and 8 weeks postoperatively. Best-corrected visual acuity (BCVA), phacoemulsification power, and effective phacoemulsification time (EPT) were evaluated. RESULTS In the biaxial group, median foveal thickness changed from 160 microm preoperatively to 168 microm 8 weeks postoperatively (p=0.018…

AdultMaleMicrosurgerymedicine.medical_specialtyVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityFoveal thicknessMacular EdemaCornea03 medical and health sciencesPostoperative Complications0302 clinical medicineOptical coherence tomographyOphthalmologyBlood-Retinal BarrierHumansMedicineMacula LuteaProspective StudiesIntraoperative ComplicationsAgedAged 80 and overPhacoemulsificationmedicine.diagnostic_testbusiness.industrySignificant differenceGeneral MedicinePhacoemulsificationMiddle AgedCataract surgeryeye diseasesOphthalmologySmall incision030221 ophthalmology & optometryFemalesense organsmedicine.symptomCoaxialbusinessTomography Optical Coherence030217 neurology & neurosurgeryEuropean Journal of Ophthalmology
researchProduct

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004

Abstract Purpose: No chemotherapy regimen, including the widely used combination of gemcitabine/cisplatin, confers significantly improved survival over any other in metastatic non-small cell lung cancer (NSCLC); however, the selection of patients according to key genetic characteristics can help to tailor chemotherapy. Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. Experimental Design: Patients were part of a large randomized trial carried out from September 1998 to July 2000, comparing gemcitabine/cisplatin versus gemcit…

AdultMaleOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsDNA RepairRibonucleoside Diphosphate Reductasemedicine.medical_treatmentAntineoplastic AgentsBiologyVinorelbineDeoxycytidineCarcinoma Non-Small-Cell LungInternal medicineRibonucleotide ReductasesmedicineHumansRNA MessengerLung cancerAgedCisplatinChemotherapyPredictive markerTumor Suppressor ProteinsDNAMiddle AgedEndonucleasesPrognosismedicine.diseaseGemcitabineChemotherapy regimenGemcitabineDNA-Binding ProteinsTreatment OutcomeOncologyFemaleCisplatinERCC1medicine.drugClinical Cancer Research
researchProduct

Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer

2005

&lt;i&gt;Background:&lt;/i&gt; Induction chemotherapy followed by surgical resection or definitive radiotherapy for patients affected by stage IIIA N2 bulky non-small cell lung cancer (NSCLC) has been investigated in several trials. &lt;i&gt;Patients and Methods:&lt;/i&gt; In this present study, 52 patients with stage IIIA N2 bulky NSCLC with cytologically or histologically confirmed mediastinal lymph node involvement received paclitaxel 175 mg/mq on day 1, carboplatin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on day 1 and 8 every 3 weeks for three cycles as induction chemotherapy. &lt;i&gt;Results:&lt;/i&gt; Objective response (4 complete remission and 36 partial remission) was achieved i…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentDeoxycytidineAntimetaboliteDisease-Free SurvivalDrug Administration ScheduleCarboplatinchemistry.chemical_compoundCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedNeoplasm StagingChemotherapybusiness.industryRemission InductionInduction chemotherapyLung cancer Paclitaxel Carboplatin stage III ChemotherapyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineCarboplatinrespiratory tract diseasesSurgeryRadiation therapyTreatment OutcomeOncologychemistryPaclitaxelChemotherapy AdjuvantFemaleRadiotherapy Adjuvantbusinessmedicine.drug
researchProduct